Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vir Biotechnology, Inc. (VIR)
:VIR
Holding VIR?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.87Last Year’s EPS
-0.86Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 12, 2020
|% Change Since: 34.98%
|Next Earnings Date:Mar 26, 2020
Earnings Call Sentiment|Neutral
The call highlighted significant strategic achievements such as the licensing agreement with Sanofi and promising clinical trial results in the hepatitis delta program, which were somewhat offset by increased R&D expenses and decreased cash reserves due to the Sanofi transaction. Overall, the company's strategic moves suggest a strong potential for growth in the future.Company Guidance
During the Q3 2024 earnings call, Vir Biotechnology provided several key metrics and strategic updates, highlighting significant advancements and future guidance. The company successfully closed an exclusive worldwide licensing agreement with Sanofi, integrating three clinical-stage masked T-cell engagers and the PRO-XTEN protease-cleavable masking platform into their portfolio. Vir is making robust progress in its hepatitis programs, including the Phase II SOLSTICE trial for hepatitis delta, where preliminary data showed virologic suppression below quantification limits in all 11 participants of the de novo combination cohort. The company estimates there are approximately 100,000 hepatitis delta patients in the U.S. and 200,000 in Europe, with limited treatment options available. Financially, Vir reported R&D expenses of approximately $195 million for Q3 2024, reflecting a $103 million expense related to the Sanofi transaction. The company's cash balance stood at approximately $1.19 billion, and they have adjusted their full-year 2024 GAAP expense guidance to $660-$680 million. Future plans include presenting data from their hepatitis programs at the AASLD conference in November and sharing preliminary monotherapy data for their T-cell engager programs in Q1 2025.Successful Licensing Agreement with Sanofi
Closed an exclusive worldwide licensing agreement with Sanofi, including three clinical stage masked T-cell engagers and the PRO-XTEN protease-cleavable masking platform for oncology and infectious diseases.
Promising Hepatitis Delta Clinical Trial Results
In the SOLSTICE trial, all participants in the de novo combination cohort achieved virologic suppression below the lower limit of quantification after 24 weeks, with no treatment-related serious adverse events.
Fast Track Designation for HDV Treatment
Received Fast Track Designation from the U.S. FDA for the combination of tobevibart and elebsiran for hepatitis delta.
Introduction of New CFO and Strategic Restructuring
Jason O'Byrne joins as CFO with a focus on disciplined capital deployment. Implemented a strategic restructuring initiative to streamline operations and prioritize clinical stage pipeline opportunities.
---
VIR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VIR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | $7.49 | $9.26 | +23.63% |
| Aug 01, 2024 | $9.73 | $9.21 | -5.34% |
| May 02, 2024 | $9.18 | $10.39 | +13.18% |
| Feb 22, 2024 | $10.30 | $11.53 | +11.94% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Vir Biotechnology, Inc. (VIR) report earnings?
Vir Biotechnology, Inc. (VIR) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Vir Biotechnology, Inc. (VIR) earnings time?
Vir Biotechnology, Inc. (VIR) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VIR EPS forecast?
VIR EPS forecast for the fiscal quarter 2024 (Q4) is -0.87.
---